Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 16 November 2012.
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: final appraisal determination document
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: consultee and commentator comments on the ACD
Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: comments on the ACD received from the public through the NICE website
This page was last updated: 29 October 2012